Gene Therapy LentiGlobin Unlikely Cause of Blood Cancer in Early Trial, Bluebird Says
News
LentiGlobin, Bluebird Bio’s investigational gene therapy for sickle cell disease (SCD), is unlikely to be the cause of a blood cancer that arose in one of the patients who received ... Read more